Cancer NetworkOriginal article
<![CDATA[ADI-212 Receives FDA IND Clearance for Castration-Resistant Prostate Cancer]]>
Phase 1ADI-212Positive
AI Analysis
Summary
ADI-212, an armored allogeneic gamma delta 1 CAR T cell therapy, has received FDA IND clearance for metastatic castration-resistant prostate cancer. Phase 1 trial enrollment is planned to begin in Q4 2026.
Clinical Trial Data
Phase
1
Outcome Details
IND clearance received from FDA
Importance:6/10
Sentiment:
0.80
IND clearanceCAR-T therapyProstate cancerPhase 1Allogeneic
Read the original article
Published by Cancer Network on August 28, 2026 2:30 PM